

Alessandra Curioni-Fontecedro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5161632/publications.pdf>

Version: 2024-02-01

32
papers

1,115
citations

516710

16
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

2406
citing authors

#	ARTICLE	IF	CITATIONS
1	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 1308-1320.	0.9	238
2	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	10.7	172
3	Automated detection of lung cancer at ultralow dose PET/CT by deep neural networks – Initial results. <i>Lung Cancer</i> , 2018, 126, 170-173.	2.0	90
4	How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. <i>ESMO Open</i> , 2019, 4, e000765.	4.5	85
5	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation – Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1897-1905.	1.1	68
6	Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer. <i>Radiation Oncology</i> , 2018, 13, 102.	2.7	44
7	Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 6345-6354.	7.0	43
8	Mutant HRAS as novel target for MEK and mTOR inhibitors. <i>Oncotarget</i> , 2015, 6, 42183-42196.	1.8	40
9	Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. <i>Clinical Lung Cancer</i> , 2019, 20, 391-396.	2.6	36
10	A new era of oncology through artificial intelligence. <i>ESMO Open</i> , 2017, 2, e000198.	4.5	35
11	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1647-1656.	1.1	34
12	Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. <i>PLoS ONE</i> , 2016, 11, e0147682.	2.5	32
13	Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma. <i>Frontiers in Oncology</i> , 2021, 11, 660039.	2.8	28
14	<i>STRN</i> <i>ALK</i> Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	21
15	Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. <i>Lung Cancer</i> , 2022, 166, 270-278.	2.0	21
16	Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1299.	2.8	20
17	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 752-762.	1.1	17
18	The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2013, 2, 27.	5.0	14

#	ARTICLE	IF	CITATIONS
19	Cytosolic pH regulates proliferation and tumour growth by promoting expression of cyclin D1. <i>Nature Metabolism</i> , 2020, 2, 1212-1222.	11.9	11
20	In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening. <i>Journal of Translational Medicine</i> , 2020, 18, 163.	4.4	11
21	Patient-reported outcomes (PRO) from the phase 2 CodeBreak 100 trial evaluating sotorasib in <i>KRAS</i> p.G12C mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9057-9057.	1.6	9
22	Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: safety and clinical outcomes. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 1297-1305.	1.4	9
23	True abscopal effect in a patient with metastatic non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 194.	2.7	8
24	Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). <i>British Journal of Cancer</i> , 2019, 120, 968-974.	6.4	7
25	Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2022, 166, 287-299.	2.8	7
26	Melanoma patients with additional primary cancers: a single-center retrospective analysis. <i>Oncotarget</i> , 2019, 10, 3373-3384.	1.8	4
27	Surgical management of lung cancer during the COVID-19 pandemic â€œ a narrative review and single-centre report. <i>Swiss Medical Weekly</i> , 2022, 152, w30109.	1.6	3
28	Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 75.	3.7	3
29	Clear cell adenocarcinoma of the lung and its driver mutation. <i>Cancer Treatment Communications</i> , 2013, 1, 6-8.	0.4	1
30	Chromosomal aberrations of cancerâ€™testis antigens in myeloma patients. <i>Hematological Oncology</i> , 2015, 33, 159-163.	1.7	1
31	The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 588563.	2.8	1
32	Reply to Authors. <i>ESMO Open</i> , 2019, 4, e000809.	4.5	0